David Platt - BIOXYTRAN INC President CEO, Director

<div class='circular--portrait' style='background:#8A0CCF;color: white;font-size:4em;padding-top: 25px;;'>BI</div>
BIXT -- USA Stock  

USD 0.44  0.06  12.20%

Dr. David Platt, Ph.D., is President, Chief Executive Officer, Director of the Company. Dr. Platt is a worldrenowned expert in carbohydrate chemistry and has founded three publiclytraded companies, creating nearly 1B for investors. He has raised 150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to Oxygen Therapy, Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 where he served as chief executive officer from 2010 to April 1, 2015 and as a director from March 2016 to June 8, 2016, and from 2001 to 2009, Dr. Platt was a founder, Chief Executive Officer and Chairman of the Board at ProPharmaceuticals, Inc. . From 1995 to 2000 Dr. Platt was the founder of International Gene Group . Dr. Platt received a Ph.D. in Chemistry in 1988 from Hebrew University in Jerusalem. In 1989, Dr. Platt was a research fellow at the Weizmann Institute of Science, Rehovot, Israel, and from 1989 to 1991, was a research fellow at the Michigan Foundation . From 1991 to 1992, Dr. Platt was a research scientist with the Department of Internal Medicine at the University of Michigan. Dr. Platt has published peerreviewed articles and holds many patents, primarily in the field of carbohydrate chemistry.
Age: 63  CEO Since 2018      
617-454-1199  http://www.bioxytraninc.com

Management Efficiency

The company has return on total asset (ROA) of (734.91) % which means that it has lost $734.91 on every $100 spent on asset. This is way below average.
The company currently holds 589.28 K in liabilities. BIOXYTRAN INC has Current Ratio of 0.03 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Found 8 records

CEO Since

Lars SoerensenNovo Nordisk AS
Ludwig HantsonAlexion Pharmaceuticals
David HallalAlexion Pharmaceuticals
Lars JoergensenNovo Nordisk AS
Paul PerreaultCsl Ltd
Leonard BellAlexion Pharmaceuticals
Leonard SchleiferRegeneron Pharmaceuticals

Company Summary

Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company was founded in 2017 and is headquartered in Newton, Massachusetts. BIOXYTRAN INC operates under Biotechnology classification in USA and is traded on BATS Exchange.BIOXYTRAN INC [BIXT] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

BIOXYTRAN INC Leadership Team

Anders Utter, Independent DirectorView
Ola Soderquist, CFO, Treasurer, SecretaryView
Henry Esber, Independent DirectorView
Dale Conaway, Independent DirectorView
David Platt, President CEO, DirectorView
Alan Hoberman, Independent DirectorView

Stock Performance Indicators

Current Sentiment - BIXT

BIOXYTRAN INC Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in BIOXYTRAN INC. What is your opinion about investing in BIOXYTRAN INC? Are you bullish or bearish?
50% Bullish
50% Bearish

BIOXYTRAN INC Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for BIOXYTRAN INC and Seattle Genetics. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..